These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24294981)

  • 1. Liposomal codelivery of a synergistic combination of bioactive lipids in the treatment of acute myeloid leukemia.
    Tan KB; Ling LU; Bunte RM; Chng WJ; Chiu GN
    Nanomedicine (Lond); 2014 Aug; 9(11):1665-79. PubMed ID: 24294981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia.
    Tan KB; Ling LU; Bunte RM; Chng WJ; Chiu GN
    J Control Release; 2012 Jun; 160(2):290-8. PubMed ID: 22100388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceramide Analogue SACLAC Modulates Sphingolipid Levels and
    Pearson JM; Tan SF; Sharma A; Annageldiyev C; Fox TE; Abad JL; Fabrias G; Desai D; Amin S; Wang HG; Cabot MC; Claxton DF; Kester M; Feith DJ; Loughran TP
    Mol Cancer Res; 2020 Mar; 18(3):352-363. PubMed ID: 31744877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
    Stover TC; Sharma A; Robertson GP; Kester M
    Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
    Xu L; Zhang Y; Gao M; Wang G; Fu Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
    Estella-Hermoso de Mendoza A; Castello-Cros R; Imbuluzqueta E; Cirauqui C; Pippa R; Odero MD; Blanco-Prieto MJ
    J Biomed Nanotechnol; 2015 Apr; 11(4):691-701. PubMed ID: 26310075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
    Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
    Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Codelivery of a Homoserine Derived Ceramide Analogue and Curcumin to Tumor Vasculature Inhibits Mouse Tumor Growth.
    Barui S; Saha S; Yakati V; Chaudhuri A
    Mol Pharm; 2016 Feb; 13(2):404-19. PubMed ID: 26716471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells.
    Lu Y; Wu J; Wu J; Gonit M; Yang X; Lee A; Xiang G; Li H; Liu S; Marcucci G; Ratnam M; Lee RJ
    Mol Pharm; 2007; 4(5):707-12. PubMed ID: 17708654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
    Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
    Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular and serum stability of liposomal 2',3'-dideoxycytidine. Effect of lipid composition.
    Makabi-Panzu B; Gourde P; Désormeaux A; Bergeron MG
    Cell Mol Biol (Noisy-le-grand); 1998 Mar; 44(2):277-84. PubMed ID: 9593578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
    Eriksson A; Chantzi E; Fryknäs M; Gullbo J; Nygren P; Gustafsson M; Höglund M; Larsson R
    Leuk Res; 2017 Dec; 63():41-46. PubMed ID: 29100024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
    Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
    J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo.
    Yang L; Weng W; Sun ZX; Fu XJ; Ma J; Zhuang WF
    Biochem Biophys Res Commun; 2015 May; 460(4):903-8. PubMed ID: 25824043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Acute Myeloid Leukemia Using Sphingosine Kinase 1 Inhibitor-Loaded Liposomes.
    Nguyen TM; Jambhrunkar M; Wong SS; Ross DM; Joyce P; Finnie JW; Manavis J; Bremmell K; Pitman MR; Prestidge CA
    Mol Pharm; 2023 Aug; 20(8):3937-3946. PubMed ID: 37463151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. l-Asparaginase-mediated downregulation of c-Myc promotes 1,25(OH)
    Song JH; Park E; Kim MS; Cho KM; Park SH; Lee A; Song J; Kim HJ; Koh JT; Kim TS
    Int J Cancer; 2017 May; 140(10):2364-2374. PubMed ID: 28224619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lipids C2- and C16-ceramide form large stable channels. Implications for apoptosis.
    Siskind LJ; Colombini M
    J Biol Chem; 2000 Dec; 275(49):38640-4. PubMed ID: 11027675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma.
    Dhule SS; Penfornis P; He J; Harris MR; Terry T; John V; Pochampally R
    Mol Pharm; 2014 Feb; 11(2):417-27. PubMed ID: 24380633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
    Li H; Xu S; Quan J; Yung BC; Pang J; Zhou C; Cho YA; Zhang M; Liu S; Muthusamy N; Chan KK; Byrd JC; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2015 Jun; 12(6):2010-8. PubMed ID: 25871632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.